人惡性非霍奇金淋巴瘤患者的自然殺傷細(xì)胞NK-9

??【編號(hào)】：NK-92

??【名稱】：人惡性非霍奇金淋巴瘤患者的自然殺傷細(xì)胞NK-9

??【規(guī)格】：株

??【價(jià)格】：1800

　　人惡性非霍奇金淋巴瘤患者的自然殺傷細(xì)胞

　　細(xì)胞名稱：NK-92人惡性非霍奇金淋巴瘤患者的自然殺傷細(xì)胞（暫不供應(yīng)）

　　描述：NK-92是從一位患有急進(jìn)性非霍奇金淋巴瘤的50歲白人男性外周血單核細(xì)胞衍生來(lái)的一株白細(xì)胞介素-2依賴型NK細(xì)胞株。這株細(xì)胞對(duì)很多惡性細(xì)胞有細(xì)胞毒性；鉻釋放試驗(yàn)顯示它能殺死K562和Daudi細(xì)胞。 NK-92細(xì)胞(經(jīng)過(guò)照射以防止增殖)可以有效地用于血液中白血病的體外免疫清掃而不危及血細(xì)胞的功能。 NK-92細(xì)胞有以下特征： CD2, CD7, CD11a, CD28, CD45, CD54表面標(biāo)記陽(yáng)性，CD56亮；CD1, CD3, CD4, CD5, CD8, CD10, CD14, CD16, CD19, CD20, CD23, CD34和HLA-DR表面標(biāo)記陰性。

　　動(dòng)物種別：人

　　性別：男

　　組織來(lái)源：惡性非霍奇金淋巴瘤患者的自然殺傷細(xì)胞,

　　形態(tài)：淋巴母細(xì)胞

　　培養(yǎng)基和添加劑：MEMα-培養(yǎng)基(GIBCO,貨號(hào)12000022，添加NaHCO3 1.5g/L,100-200單位/ml重組 IL-2)，90%；優(yōu)質(zhì)胎牛血清，10%。氣相：空氣，95%；二氧化碳，5%。溫度：37攝氏度。

　　供應(yīng)限制：A。僅供研究之用。

　　REFERENCE：Gong JH , et al. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658, 1994. PubMed: 8152260 Klingemann HG , et al. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol. Blood Marrow Transplant. 2: 68-75, 1996. PubMed: 9118301 Tam YK , et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther. 10: 1359-1373, 1999. PubMed: 10365666 Klingemann HG , Miyagawa B . Purging of malignant cells from blood after short ex vivo incubation with NK-92 cells. Blood 87: 4913-1914, 1996. PubMed: 8639869 Komatsu F , Kajiwara M . Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells. Oncol. Res. 10: 483-489, 1998. PubMed: 10338151 Yan Y , et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin. Cancer Res. 4: 2859-2868, 1998. PubMed: 9829753 Maki G , et al. Induction of sensitivity to NK-mediated cytotoxicity by TNF-alpha treatment: possible role of ICAM-3 and CD44. Leukemia 12: 1565-1572, 1998. PubMed: 9766501 Nagashima S , et al. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood 91: 3850-3861, 1998. PubMed: 9573023 Tam YK , et al. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J. Hematother. 8: 281-290, 1999.

上一篇：人惡性非霍奇金淋巴瘤患者的自然殺傷細(xì)胞NK-9		下一篇：大鼠肺泡巨噬細(xì)胞NR8383

人惡性非霍奇金淋巴瘤患者的自然殺傷細(xì)胞

產(chǎn)品明細(xì)

熱銷產(chǎn)品 新品上架

產(chǎn)品推薦 相關(guān)產(chǎn)品

人惡性非霍奇金淋巴瘤患者的自然殺傷細(xì)胞

產(chǎn)品明細(xì)

熱銷產(chǎn)品 新品上架

產(chǎn)品推薦 相關(guān)產(chǎn)品

　　人惡性非霍奇金淋巴瘤患者的自然殺傷細(xì)胞

熱銷產(chǎn)品新品上架

產(chǎn)品推薦相關(guān)產(chǎn)品